The UK’s competition regulator is trying to reinstate a record £90 million (US$116.2 million) fine against drug companies Pfizer and Flynn for raising the price of an anti-epilepsy drug by up to 2,600% per cent, after its decision was overturned last year, reported The Financial Times.
The Competition and Markets Authority is arguing that the Competition Appeals Tribunal “erred in law” when it upheld Pfizer’s appeal against the fine.
The case pits the regulator against big pharma and could set a precedent determining the extent to which UK and European competition regulators can limit drug pricing. It hinges on the price of phenytoin sodium pills, used by roughly 48,000 epilepsy patients in the UK to control seizures.
Pfizer passed the distribution of the drug, previously branded Epanutin, to Flynn Pharma in 2012, which sold it as a generic, unbranded drug. Generic drugs are not subject to the same price controls as branded medicines, and the price of 100mg packs, for example, rose from £2.83 to £67.50 overnight (US$3.65 to US$87.12).
NHS spending on phenytoin sodium capsules jumped from £2 million (US$2.58 million) a year in 2012 to roughly £50 million (US$64.5 million) the following year. The regulator stated both companies each held a dominant position in their respective markets for the manufacture and supply of the drug, and that they had abused that position by charging excessive and unfair prices. It fined Pfizer £84.2 million (US$108.7 million) and Flynn £5.2 million (US$6.1 million).
Full Content: Financial Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Urged to Enforce Rarely Used Antitrust Law Against Retail Giants
Mar 28, 2024 by
CPI
UK’s Fingleton Bolsters Team with New Additions
Mar 28, 2024 by
CPI
Britain’s Competition Regulator Clears Aviva’s Acquisition of AIG Life UK
Mar 28, 2024 by
CPI
White House Implements New AI Safeguards to Protect Rights and Safety
Mar 28, 2024 by
CPI
Denver Court Sets August Date for Kroger-Albertsons Merger Showdown
Mar 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Real Estate & Antitrust
Mar 27, 2024 by
CPI
Systematic National Evidence of Steering by Real Estate Agents
Mar 27, 2024 by
CPI
Compliance Now! Actionable Antitrust Advice for the Residential Real Estate Industry
Mar 27, 2024 by
CPI
Real Estate Commissions: Some Insights from the Economics of Multi-Sided Platforms
Mar 27, 2024 by
CPI
New Ideas for Promoting Real Estate Brokerage Price Competition
Mar 27, 2024 by
CPI